Consolidated Portfolio Review Corp Acquires Shares of 3,136 Boston Scientific Corporation $BSX

Key Points

• Consolidated Portfolio Review Corp has acquired 3,136 shares of Boston Scientific, valued at approximately $337,000, during the 2nd quarter.
• Boston Scientific reported a 22.8% increase in revenue year-over-year for the last quarter, amounting to $5.06 billion, while earnings per share exceeded analysts' expectations.
• Recent analyst upgrades have raised Boston Scientific's target price significantly, with Raymond James Financial increasing theirs from $121.00 to $124.00, maintaining a "strong-buy" rating.

Consolidated Portfolio Review Corp bought a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,136 shares of the medical equipment provider's stock, valued at approximately $337,000.

Other large investors have also recently made changes to their positions in the company. 1248 Management LLC bought a new stake in Boston Scientific in the first quarter worth about $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the 1st quarter worth approximately $27,000. Sound Income Strategies LLC lifted its stake in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new position in Boston Scientific during the 2nd quarter valued at $37,000. Finally, Activest Wealth Management grew its position in Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 373 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $96.36 on Friday. The firm has a 50 day moving average of $103.10 and a 200 day moving average of $102.06. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $142.78 billion, a price-to-earnings ratio of 57.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Raymond James Financial boosted their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Wells Fargo & Company upped their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. BTIG Research raised their target price on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a "buy" rating in a research report on Wednesday. Needham & Company LLC reiterated a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a report on Wednesday. Finally, UBS Group increased their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and an average target price of $120.79.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.